ClinicalTrials.gg
CompletedNCT00115570Updated May 20, 2016

Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents

A Phase 3 interventional study of Insulin glulisine and insulin lispro in Diabetes Mellitus, Insulin-Dependent, sponsored by Sanofi. Completed at 1 site in United States. Open to participants aged 4 Years to 17 Years. Per ClinicalTrials.gov, last updated 2016-05-20.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
572
Allocation
Randomized
Ages
4 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing insulin glulisine in Diabetes Mellitus, Type 1 — none open to participants now, none under way, none of them phase 3. insulin glulisine · Diabetes Mellitus, Type 1.

Enrollment
Largest of 25
572 · median 72
Started
2005
with 4 others
Phase 3
6 of 26
none open now
Registered
2nd of 26
by date
Lead sponsor
15 of 26
Sanofi

Among the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 1, this one has the largest enrollment of the 25 interventional ones that give a count, is one of 5 that started in 2005, is one of 6 in phase 3, and was the 2nd registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

None of the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 1 is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →

About insulin glulisine

insulin glulisine: first FDA approval 2004 (APIDRA SOLOSTAR), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 4 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 1 as a file.
02

Study summary

The purpose of this study is to determine if insulin glulisine (Apidra) is as safe and effective a rapid acting insulin as insulin lispro (Humalog) in children and adolescents with type 1 diabetes mellitus.

03

Conditions studied

  • Diabetes Mellitus, Insulin-Dependent

Keywords

  • Diabetes,Insulin-Dependent, pediatric,rapid acting injection
04

Who can participate

Ages eligible
4 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Girls/boys, 4-17 years, inclusive;
  • Girls not yet of or, if sexually active, agree to use reliable medically accepted measure during study;
  • Type 1 diabetes mellitus established in medical history: for example, but not limited to, clear signs of insulinopenia (polyuria, polydipsia, polyphagia, weight loss, ketonuria, ketoacidosis); or glutamic acid decarboxylase (GAD) antibody indicative of type 1 diabetes measured at any time before study; or requiring continuous insulin therapy from time of diagnosis;
  • Onset of diabetes at least 1 year prior to visit 1 (V1) of study;
  • Uninterrupted insulin therapy for at least 1 year before V1 of study;
  • At V1, on stable insulin regimen of either NPH or insulin glargine as basal insulin and willing to have multiple daily injections of insulin;
  • at V1 between ≥ 6.0 and ≤11.0 %;
  • Ability/willingness to do blood glucose monitoring using sponsor-provided glucometer and subject diary.

Exclusion criteria

Exclusion Criteria:

  • Active proliferative diabetic retinopathy, defined by application of focal or panretinal photocoagulation or vitrectomy, 6 months before V1, or any other unstable/rapidly progressing retinopathy requiring surgical treatment (including laser photocoagulation) during study;
  • Diabetes other than type 1 diabetes mellitus;
  • Pregnancy (positive pregnancy blood test at V1) or breastfeeding;
  • Pancreatectomized subjects;
  • Subjects who have had pancreas and/or islet cell transplants;
  • Treatment with any anti-diabetic oral agent at any time from diabetes diagnosis;
  • Treatment with systemic in last month before V1;
  • Subjects on pump therapy during last 2 months before V1;
  • Subjects requiring excessively high doses of insulin ("resistant" patients), for example, but not limited to, subjects receiving over 150 IU per day;
  • Likelihood of needing treatment during study period with drugs not permitted by protocol
  • Treatment with any drug in last month before V1;
  • History of primary seizure disorders;
  • History of severe hypoglycemic episode accompanied by seizure and/or coma or diabetic ketoacidosis leading to hospitalization, or to care in emergency ward, 3 months prior to V1;
  • History of hypoglycemia unawareness;
  • History of to insulin or insulin analogs or any of the in insulin glulisine formulation or any of the excipients in other study insulin preparations formulations;
  • hepatic, neurologic, endocrine, active cancer, or other major systemic disease making implementation of protocol or interpretation of study results difficult and would, in the opinion of the investigator, preclude safe participation of subject in protocol;
  • History of cardiac abnormalities and/or cardiovascular disorders;
  • History of drug/alcohol abuse;
  • Impaired hepatic function shown by, but not limited to, (ALT) or aspartate aminotransferase (AST) greater than twice the normal upper limit for age at V1;
  • Impaired renal function shown by, but not limited to, serum creatinine greater than 1.5 times upper limit for age at V1;
  • Non fasting triglyceride level of >500 mg/dL (5.7 mmol/L) at V1;
  • Parent/legally authorized representative unable to understand nature, scope, possible consequences of study;
  • Parent/legally authorized representative unable to read/write;
  • Subjects unlikely to comply with protocol, e.g. inability/unwillingness to participate in adequate training, uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing study;
  • Children/relatives of employee of sponsor or of sponsor representatives;
  • Children or relatives of investigator, any sub-investigator, research assistant, pharmacist, study coordinator or other staff directly involved in conduct of protocol;
  • Subjects who have previously been treated with insulin glulisine.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
572 participants (actual)

Study arms

  • Experimental
    Insulin Glulisine

    Insulin Glulisine (100UI/ml), at least twice daily, in association with basal insulin therapy (NPH insulin or insulin glargine for a maximum of 26 weeks

    Drug: Insulin glulisine · Drug: insulin glargine · Drug: NPH insulin

  • Active comparator
    Insulin Lispro

    Insulin Lispro (100UI/ml) Subcutaneous (SC) injection , at least twice daily, in association with basal insulin therapy (NPH insulin or insulin glargine ) for a maximum of 30 weeks

    Drug: insulin lispro · Drug: insulin glargine · Drug: NPH insulin

Interventions

06

What researchers measure

Primary outcomes

  1. Change in total glycated hemoglobin measured as HbA1c equivalents (GHb )from baseline to endpoint

    Time frame: week 26 or last observed treatment

Secondary outcomes

  1. Change from Baseline in GHb at weeks 12 and 26

    Time frame: weeks 12 and 26

  2. Change from Baseline in Self-monitored glucose parameters

    Time frame: weeks 4, 12, 18, 26, and endpoint;

  3. Incidence of Symptomatic hypoglycemia

    Time frame: first dose of study up to last dose

  4. Change from Baseline in basal insulin dose

    Time frame: week 4, 12, 18, 26, and endpoint;

07

Study locations

1 site
  • Childrens Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15213, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2005, a primary completion of Nov 2006 and a completion of Nov 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2005
First posted
Jun 24, 2005
Start
Apr 2005
Primary completionActual
Nov 2006
CompletionActual
Nov 2006
Last update
May 20, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00115570
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jun 24, 2005
Start date
Apr 2005
Primary completion
Nov 2006
Completion
Nov 2006
Last update
May 20, 2016

Study contacts

Dr Arethi PHILOTHEOU
principal investigator · UCT Diabetes Clinical Trials Unit - Faculty of Health Sciences - South-Africa

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin glulisine

Start the discussion